Skip to main content
Premium Trial:

Request an Annual Quote

EC Gives European Consortium $16M to Study How RNAi Can Help Rx Development

NEW YORK (GenomeWeb News) — A UK research institute will lead an €11.8-million ($16-million) research consortium that will study the potential uses for RNA interference in treating disease.
 
The Sainsbury Institute at the John Innes Center in Norwich said the European Commission-funded consortium will comprise 17 labs in nine European countries. The group will be called Silencing RNAs: Organizers and Coordinators of Complexity in Eukaryotic Organisms.
 
Researchers involved in the programs will study the uses of RNAi in plant and animal systems, including humans.
 
The Institute said it will use model systems that will allow scientists to conduct experiments it could not perform in humans, but that could translate into therapeutics.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.